Hiraman/E+ via Getty Images
- Pharming Group N.V. (NASDAQ:PHAR) said total revenues are expected to increase by 19% to approximately $245 million for 2023.
- “We seek to significantly expand the leniolisib market opportunity by pursuing development of leniolisib for additional primary immunodeficiencies (PIDs) beyond APDS, including a Phase 2 proof of concept clinical trial protocol in PIDs with immune dysregulation linked to PI3Kẟ signaling planned to start in 2Q 2024,” Sijmen de Vries, Chief Executive Officer, commented.
- Sees Joenja 2023 revenues of approximately $18 million driven by the continued increase during the fourth quarter in patients on paid therapy.
- Expects full year 2023 RUCONEST revenues to increase by 10% to approximately $227 million, significantly exceeding our previous low single digit growth guidance.
- Preliminary, unaudited cash and cash equivalents, together with restricted cash and marketable securities, are expected to total $215.0 million at the end of 2023, compared to $199.2 million at the end of the third quarter 2023 and $208.7 million at the end of 2022.
- Source: Press Release